Genotypic and phenotypic analyses of HIV-1 in antiretroviral-experienced patients treated with tenofovir DF

AIDS

Volumn 16, Issue 9, 2002, Pages 1227-1235

  Margot, Nicolas A ^a   Isaacson, Erica ^a   McGowan, Ian ^a   Cheng, Andrew K ^a   Schooley, Robert T ^a   Miller, Michael D ^a  

^a GILEAD SCIENCES   (United States)

Author keywords

AIDS; Antiretroviral experienced; HIV 1; PMPA; Resistance; TDF; Tenofovir; Tenofovir DF

Indexed keywords

ABACAVIR; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTIRETROVIRUS AGENT; DIDANOSINE; LAMIVUDINE; PLACEBO; PROTEINASE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; TENOFOVIR DISOPROXIL; THYMIDINE DERIVATIVE; ZIDOVUDINE; ADENINE; DRUG DERIVATIVE; ORGANOPHOSPHORUS COMPOUND; PHOSPHONIC ACID DERIVATIVE; TENOFOVIR; VIRUS RNA;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG RESPONSE; DRUG SENSITIVITY; GENOTYPE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PHASE 2 CLINICAL TRIAL; PHENOTYPE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REBOUND; VIRAL GENETICS; VIREMIA; VIRUS LOAD; VIRUS MUTATION; VIRUS REPLICATION; VIRUS RESISTANCE; ANTIBIOTIC RESISTANCE; DRUG EFFECT; ENZYMOLOGY; GENETICS; METABOLISM; MUTATION; PHYSIOLOGY; TIME; VIROLOGY;

ADENINE; DOUBLE-BLIND METHOD; DRUG RESISTANCE, VIRAL; GENOTYPE; HIV INFECTIONS; HIV-1; HIV-1 REVERSE TRANSCRIPTASE; HUMAN; MUTATION; ORGANOPHOSPHORUS COMPOUNDS; PHENOTYPE; RNA, VIRAL; TIME FACTORS; HUMANS; PHOSPHONIC ACIDS;

EID: 0037076708     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200206140-00004     Document Type: Article

References (27)

1. Drug resistance and its implications in the management of HIV infection
2. Differential antiherpesvirus and antiretrovirus effects of the (S) and (R) enantiomers of acyclic nucleoside phosphonates: Potent and selective in vitro and in vivo antiretrovirus activities of (R)-9-(2-phosphonomethoxypropyl)-2,6-diaminopurine
3. Anti-human immunodeficiency virus activity and cellular metabolism of a potential prodrug of the acyclic nucleoside phosphonate 9-R-(2-phosphonomethoxypropyl)adenine (PMPA), bis(isopropyloxymethylcarbonyl)PMPA
4. Metabolic pathways for activation of the antiviral agent 9-(2-phosphonylmethoxyethyl)adenine in human lymphoid cells
5. Synthesis, in vitro biological evaluation and oral bioavailability of prodrugs of the antiretroviral agent 9-[2-(phosphonomethoxy)-propyl]adenine (PMA)
6. Bis(POC)PMPA, an orally bioavailable prodrug of the antiretroviral agent PMPA
7. Antiretroviral efficacy and pharmacokinetics of oral bis(isopropyloxymethyl)-9(2-phosphonylmethoxypropyl) adenine in mice
8. The safety and efficacy of PMPA prodrug monotherapy: Preliminary results of a phase I/II dose-escalation study
9. Tenofovir DF in highly antiretroviral-experienced patients: Results from a 48-week, randomized, double-blind study
10. In vitro selection and characterization of HIV-1 with reduced susceptibility to PMPA
11. Emergence of human immunodeficiency virus type 1 variants with resistance to multiple dideoxynucleosides in patients receiving therapy with dideoxynucleosides
12. Antiviral activities of 9-R-2-phosphonomethoxypropyl adenine (PMPA) and bis(isopropyloxymethylcarbonyl)PMPA against various drug-resistant human immunodeficiency virus strains
13. Human immunodeficiency virus type 1 expressing the lamivudine-associated M184V mutation in reverse transcriptase shows increased susceptibility to adefovir and decreased replication capability in vitro
14. Identification of a mutation of codon 65 in the IKKK motif of reverse transcriptase that encodes human immunodeficiency virus resistance to 2′,3′-dideoxycytidine and 2′,3′-dideoxy-3′-thiacytidine
15. Resistance to 2′,3′-dideoxycytidine conferred by a mutation in codon 65 of the human immunodeficiency virus type 1 reverse transcriptase
16. Combination of mutations in human immunodeficiency virus type 1 reverse transcriptase required for resistance to the carbocyclic nucleoside 1592U89
17. Mutations in the pol gene of human immunodeficiency virus type 1 in infected patients receiving didanosine and hydroxyurea combination therapy
18. Patterns of HIV drug resistance in routine clinical practice: A survey of almost 12 000 samples from the USA in 1999
19. Antiviral activity of tenofovir (PMPA) against nucleoside-resistant HIV samples
20. The relation between baseline HIV drug resistance and response to antiretroviral therapy: Re-analysis of retrospective and prospective studies using a standardized data analysis plan
21. Mutations in the pol gene of human immunodeficiency virus type 1 in infected patients receiving didanosine and hydroxyurea combination therapy
22. The K65R mutation confers increased DNA polymerase processivity to HIV-1 reverse transcriptase
23. Differential influence of nucleoside analog-resistance mutations K65R and L74V on the overall mutation rate and error specificity of human immunodeficiency virus type 1 reverse transcriptase
24. Genotype and phenotype of HIV-1 in ART experienced adults prior and following therapy with Ziagen (abacavir, ABC) added to stable background therapy (ABC+SBG)
25. Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy
26. Efficacy and safety of adefovir dipivoxil with antiretroviral therapy
27. Lamivudine in combination with zidovudine, stavudine, or didanosine in patients with HIV-1 infection. A randomized, double-blind, placebo-controlled trial